Nagano Taichi, Takada Kazuki, Hashinokuchi Asato, Matsudo Kyoto, Kinoshita Fumihiko, Akamine Takaki, Kohno Mikihiro, Shimokawa Mototsugu, Takenaka Tomoyoshi, Oda Yoshinao, Yoshizumi Tomoharu
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Surgery, Saiseikai Fukuoka General Hospital, 1-3-46 Tenjin, Chuo-ku, Fukuoka, 810-0001, Japan.
Int J Clin Oncol. 2025 Jan;30(1):62-71. doi: 10.1007/s10147-024-02640-x. Epub 2024 Oct 23.
Cluster of differentiation 155 (CD155) is expressed in many tumor types. CD155 is involved in the immune avoidance of tumor cells and contributes to tumor development and progression. Therefore, CD155 is a novel target for cancer immunotherapy. The clinical significance of CD155 expression in lung squamous cell carcinoma (LUSC) has not been fully elucidated.
We performed a retrospective analysis of 264 patients with surgically resected LUSC. Immunohistochemistry was used to evaluate CD155 expression. The association of CD155 expression with clinicopathological features and clinical outcomes was assessed. We also analyzed the relationship between CD155 expression and programmed cell death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes.
Among the 264 patients, 137 patients (51.9%) were classified in the high CD155 expression group. High CD155 expression was significantly associated with pleural invasion, vascular invasion, PD-L1 positivity, and high CD3, CD4, and CD8 expressions. In multivariate analysis, the presence of pleural invasion and PD-L1 positivity were independent predictors of high CD155 expression. Kaplan-Meier curve analysis showed that high CD155 expression was significantly associated with shorter disease-free survival and overall survival. In multivariate analysis, high CD155 expression was an independent poor prognostic factor for overall survival, but not for disease-free survival. Subgroup analyses revealed that the prognostic effect of CD155 expression was observed in the PD-L1 positive group but not the PD-L1 negative group.
Our analysis revealed that high CD155 expression significantly predicted poor prognosis in patients with surgically resected LUSC, especially in patients with PD-L1-positive tumors.
分化簇155（CD155）在多种肿瘤类型中表达。CD155参与肿瘤细胞的免疫逃逸，促进肿瘤的发生发展。因此，CD155是癌症免疫治疗的一个新靶点。肺鳞状细胞癌（LUSC）中CD155表达的临床意义尚未完全阐明。
我们对264例接受手术切除的LUSC患者进行了回顾性分析。采用免疫组织化学法评估CD155表达。评估CD155表达与临床病理特征及临床结局的相关性。我们还分析了CD155表达与程序性细胞死亡配体1（PD-L1）表达及肿瘤浸润淋巴细胞之间的关系。
在264例患者中，137例（51.9%）被归类为CD155高表达组。CD155高表达与胸膜侵犯、血管侵犯、PD-L1阳性以及CD3、CD4和CD8高表达显著相关。多因素分析显示，胸膜侵犯和PD-L1阳性是CD155高表达的独立预测因素。Kaplan-Meier曲线分析表明，CD155高表达与无病生存期和总生存期缩短显著相关。多因素分析显示，CD155高表达是总生存期的独立不良预后因素，但不是无病生存期的独立不良预后因素。亚组分析显示，CD155表达的预后作用在PD-L1阳性组中观察到，而在PD-L1阴性组中未观察到。
我们的分析表明，CD155高表达显著预测手术切除的LUSC患者预后不良，尤其是PD-L1阳性肿瘤患者。
